James Golubieski
Präsident bei Foundation Venture Capital Group LLC
Profil
James M.
Golubieski is currently a Director at Actinobac Biomed, Inc., Celvive, Inc., NovoPedics, Inc., and NemaGen Discoveries, Inc. He is also the President of Foundation Venture Capital Group LLC and New Jersey Health Foundation, Inc. In the past, he worked as a Director at CellXplore, Inc., Snowdon, Inc., and GeneAssess, Inc. He was also a Principal at KPMG, Inc., Chief Financial Officer at Glendale Bancorp, and Treasurer at Learning Ally, Inc. Mr. Golubieski received his undergraduate degree from Rider University in 1978.
Aktive Positionen von James Golubieski
| Unternehmen | Position | Beginn |
|---|---|---|
Foundation Venture Capital Group LLC
 Foundation Venture Capital Group LLC Investment ManagersFinance Foundation Venture Capital Group LLC (Foundation Venture) is a venture capital firm headquartered in Princeton, New Jersey. Founded in 2006, the firm is the equity investment arm of New Jersey Health Foundation Inc. | Präsident | 01.01.2007 |
| New Jersey Health Foundation, Inc. | Präsident | - |
Celvive, Inc.
 Celvive, Inc. Miscellaneous Commercial ServicesCommercial Services Celvive, Inc. engages in the development of technology for the isolation and use of autologous cellular therapy for regenerative medicine applications. It specializes in using a closed bag system to isolate specific adult stem cells from the patients' own bone marrow. The company was founded by Hatem E. Sabaawy in 2011 and is headquartered in New Brunswick, NJ. | Direktor/Vorstandsmitglied | - |
NovoPedics, Inc.
 NovoPedics, Inc. Medical SpecialtiesHealth Technology NovoPedics, Inc. develops implantable medical devices that restore mobility to patients suffering from severe meniscus knee injuries. It provides a way to replace damaged meniscus tissue with a patented fiber-reinforced design similar to the native meniscus and can be attached to both soft tissue and bone, allowing it to be used in total meniscus replacement surgery. The company was founded by Charles J. Gatt Jr. and Michael G. Dunn in 2013 and is headquartered in New Brunswick, NJ. | Direktor/Vorstandsmitglied | - |
Actinobac Biomed, Inc.
 Actinobac Biomed, Inc. Pharmaceuticals: MajorHealth Technology Actinobac Biomed, Inc. operates as a biopharmaceutical company developing therapeutics. It offers therapeutics for indications, including blood cancers, autoimmune, inflammatory diseases and HIV. The company was founded by Scott C. Kachlany in 2009 and is headquartered in Kendall Park, NJ. | Direktor/Vorstandsmitglied | - |
Nemagen Discoveries, Inc.
 Nemagen Discoveries, Inc. Miscellaneous Commercial ServicesCommercial Services NemaGen Discoveries, Inc. is a biotech company located in Princeton, NJ. The company focuses on developing therapies for patients with allergic inflammation and mast cell-related diseases. NemaGen's unique approach to drug development involves investigating the body's natural ability to prevent unwanted inflammation following parasitic infections. Recently, NemaGen announced its participation in the NIH I-Corps program to better understand stakeholders' needs and validate the value of its therapies. The company was founded by Mark Siracusa and has been led by CEO Nicholas Shubin since 2022. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von James Golubieski
| Unternehmen | Position | Ende |
|---|---|---|
GeneAssess, Inc.
 GeneAssess, Inc. Medical/Nursing ServicesHealth Services GeneAssess, Inc. discovers, develops and commercializes novel diagnostic tests that help physicians to treat and improve outcomes for cancer patients. The firm engages in developing new diagnostic and genetic tests for assessing cancer risk based on the expression and the DNA sequence of the FRY, a putative tumor suppressor gene and a novel cancer biomarker. The company was founded by Helmut Zarbl in June 2012 and is headquartered in New Brunswick, NJ. | Direktor/Vorstandsmitglied | - |
CellXplore, Inc.
 CellXplore, Inc. BiotechnologyHealth Technology CellXplore, Inc. operates as a biotechnology company which engages in the development of biomarker-based in vitro diagnostic assays. The firm commercializes groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions. The company was founded by Kiran Madura on September 24, 2007 and is headquartered in New Brunswick, NJ. | Direktor/Vorstandsmitglied | - |
KPMG, Inc.
 KPMG, Inc. Miscellaneous Commercial ServicesCommercial Services Part of KPMG International Cooperative, KPMG, Inc. provides audit and accounting services. The company is based in Vancouver, Canada. The CEO of the Canadian company is Walter R. Pela. | Corporate Officer/Principal | - |
| ░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von James Golubieski
| Rider University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
KPMG, Inc.
KPMG, Inc. Miscellaneous Commercial ServicesCommercial Services Part of KPMG International Cooperative, KPMG, Inc. provides audit and accounting services. The company is based in Vancouver, Canada. The CEO of the Canadian company is Walter R. Pela. | Commercial Services |
| Glendale Bancorp | Finance |
Learning Ally, Inc.
 Learning Ally, Inc. Miscellaneous Commercial ServicesCommercial Services Learning Ally, Inc. provides educational support services. It produces & distributes tapes and CD-ROMs of textbooks for students as well as recordings of reference and professional materials to individuals with print disabilities such as blindness, visual impairments and dyslexia. The company was founded by Anne T. MacDonald in 1948 and is headquartered in Princeton, NJ. | Commercial Services |
CellXplore, Inc.
CellXplore, Inc. BiotechnologyHealth Technology CellXplore, Inc. operates as a biotechnology company which engages in the development of biomarker-based in vitro diagnostic assays. The firm commercializes groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions. The company was founded by Kiran Madura on September 24, 2007 and is headquartered in New Brunswick, NJ. | Health Technology |
Foundation Venture Capital Group LLC
Foundation Venture Capital Group LLC Investment ManagersFinance Foundation Venture Capital Group LLC (Foundation Venture) is a venture capital firm headquartered in Princeton, New Jersey. Founded in 2006, the firm is the equity investment arm of New Jersey Health Foundation Inc. | Finance |
| New Jersey Health Foundation, Inc. | Finance |
Snowdon, Inc.
 Snowdon, Inc. Pharmaceuticals: MajorHealth Technology Snowdon, Inc. operates as a drug discovery and development company. The firm creates and distributes computational tools and techniques for the life sciences including drug discovery and development, safety, toxicity assessment and environmental and toxicological surveillance. It provides a solution to the problems of efficiency and productivity in drug discovery by integrating an array of advanced tools with proprietary information technology to more efficiently discover new drugs and harness the flood of new disease-related protein targets presented by genomics. The company was founded by William J. Welsh and Susan M. Welsh in 2007 and is headquartered in Princeton, NJ. | Health Technology |
Actinobac Biomed, Inc.
Actinobac Biomed, Inc. Pharmaceuticals: MajorHealth Technology Actinobac Biomed, Inc. operates as a biopharmaceutical company developing therapeutics. It offers therapeutics for indications, including blood cancers, autoimmune, inflammatory diseases and HIV. The company was founded by Scott C. Kachlany in 2009 and is headquartered in Kendall Park, NJ. | Health Technology |
Celvive, Inc.
Celvive, Inc. Miscellaneous Commercial ServicesCommercial Services Celvive, Inc. engages in the development of technology for the isolation and use of autologous cellular therapy for regenerative medicine applications. It specializes in using a closed bag system to isolate specific adult stem cells from the patients' own bone marrow. The company was founded by Hatem E. Sabaawy in 2011 and is headquartered in New Brunswick, NJ. | Commercial Services |
GeneAssess, Inc.
GeneAssess, Inc. Medical/Nursing ServicesHealth Services GeneAssess, Inc. discovers, develops and commercializes novel diagnostic tests that help physicians to treat and improve outcomes for cancer patients. The firm engages in developing new diagnostic and genetic tests for assessing cancer risk based on the expression and the DNA sequence of the FRY, a putative tumor suppressor gene and a novel cancer biomarker. The company was founded by Helmut Zarbl in June 2012 and is headquartered in New Brunswick, NJ. | Health Services |
NovoPedics, Inc.
NovoPedics, Inc. Medical SpecialtiesHealth Technology NovoPedics, Inc. develops implantable medical devices that restore mobility to patients suffering from severe meniscus knee injuries. It provides a way to replace damaged meniscus tissue with a patented fiber-reinforced design similar to the native meniscus and can be attached to both soft tissue and bone, allowing it to be used in total meniscus replacement surgery. The company was founded by Charles J. Gatt Jr. and Michael G. Dunn in 2013 and is headquartered in New Brunswick, NJ. | Health Technology |
Nemagen Discoveries, Inc.
Nemagen Discoveries, Inc. Miscellaneous Commercial ServicesCommercial Services NemaGen Discoveries, Inc. is a biotech company located in Princeton, NJ. The company focuses on developing therapies for patients with allergic inflammation and mast cell-related diseases. NemaGen's unique approach to drug development involves investigating the body's natural ability to prevent unwanted inflammation following parasitic infections. Recently, NemaGen announced its participation in the NIH I-Corps program to better understand stakeholders' needs and validate the value of its therapies. The company was founded by Mark Siracusa and has been led by CEO Nicholas Shubin since 2022. | Commercial Services |
